First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms
Nuclear medicine has entered an era when we are discovering more and more molecules which can precisely target cancer cells. In this case, the molecule DOTA-LM3 is linked with the radioactive atom lutetium 177, which delivers a very short range beta particle, a high speed electron which acts like a quantum bullet in the cancer […]